Is There a Role for Second Line Therapy in Advanced Pancreatic Cancer?
FOLFIRINOX (5-FU, oxaliplatin and irinotecan) and gemcitabine based regimens are widely used for the first-line treatment for patients with advanced pancreatic adenocarcinoma. Nab-paclitaxel and gemcitabine has replaced the use of many single agent gemcitabine in these patients population. In patients who progress on the first line therapy use of either 5-FU, leucovorin and oxaliplatin (FOLFOX) or gemcitabine and nab-paclitaxel combination has become a de facto standard depending on the chemotherapy they received in first line. Progress made in first line chemotherapy has lead to more interest in refractory pancreatic cancer. This article examines the 2014 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium regarding recent developments in the treatment of refractory pancreatic cancer, as these were presented in Abstracts #296, #297, #337, #344, and #381 of the meeting.
Image: Chemotherapy regimens tested in refractory pancreatic cancer at 2014 ASCO GI Symposium
Burris HA, III, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine. 2011 May 12;364(19):1817
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. The New England Journal of Medicine. 2013 Oct 31;369(18):1691-703.
Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B et. al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47(11):1676.
Chung JW, Jang HW, Chung MJ et.al. Folfox4 as a rescue chemotherapy for gemcitabine refractory pancreatic cancer. Hepatogastroenterology 2013 Mar-Apr; 60(122):363-7.
Assaf E, Verlinde-Carvalho M, Delbaldo C, et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 2011; 80:301.
Lee MG, Lee SH, Lee SJ, et. al. 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy. Chemotherapy 2014 Jan 18;59(4):273-279.
Hosein PJ, Pastorini VH, Gomez CM, A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer Am J Clin Oncol. 2013 Apr;36(2):151-6.
Peddi PF, Co M, Wang J, et.al. Nab-paclitaxel montherapy in refractoy pancreatic adenocarcinoma J Gastrointest Oncol 2013 Dec;4(4):370-3.
Ko AH, Tempero MA, Shan YS, et. al. A mutinational phase 2 study of nanoliposomal irinotecan surcosofate (PEP02, MM-398) for patients with gemcitabine refractory metastatic pancreatic cnacer. Br J Cancer. 2013 Aug 20;109(4):920-5.
Thota R, Goff LW, Chan E. et.al. A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC). 2014 ASCO Gastrointestinal Cancers Symposium. Abstract No. 297
Bjerregaard JK, Ladekarl M, Farr KP et. al. , A randomized phase I/II study of everolimus, irinotecan, and cetuximab versus capecitabine and oxaliplatin in gemcitabine-resistant patients with pancreatic cancer. 2014 ASCO Gastrointestinal Cancers Symposium. Abstract No.337.
Zhang Y, Hochster HS, Stein S et. al. , Second-line gemcitabine plus nab-paclitaxel (G+A) for advanced pancreatic cancer (APC) after first-line FOLFIRINOX: Single institution retrospective review of efficacy and toxicity. 2014 ASCO Gastrointestinal Cancers Symposium. Abstract No.344.
Borazanci E, Schroeder K , Jameson GS et. al. , Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer. 2014 ASCO Gastrointestinal Cancers Symposium. Abstract No.381.
Nagrial A, Chin VT, Sjoquist K et. al. . Survival benefit of second-line chemotherapy in advanced pancreatic adenocarcinoma: A systematic review of the literature. . 2014 ASCO Gastrointestinal Cancers Symposium. Abstract No. 296
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011 Aug 13;378(9791):607-20.
Hoos WA, James PM, Rahib L, et.al. Pancreatic cancer clincial trials and accrual in the United States. J. Clin Oncol. 2013 Sep 20:31 (2&):3432-8.
Copyright (c) 2014 Minsig Choi, Muhammad Wasif Saif, Richard Kim
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.